Daily Archives: May 4, 2020

Junshi Biosciences and Lilly to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19

SHANGHAI and INDIANAPOLIS, May 04, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877) and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus.

At the beginning of the COVID-19 outbreak, Junshi Biosciences—a China-based biopharmaceutical company specializing in discovery, development and commercialization of novel therapies—launched one of the industry’s first R&D efforts aimed at discovering therapies to combat COVID-19. Multiple neutralizing antibodies have been engineered, with the lead asset poised to enter clinical testing in the second quarter.

“Since the outbreak of COVID-19, we have been working diligently to join the fight against the pandemic. Entering into this agreement with Lilly empowers us to accelerate the clinical development of Junshi SARS-CoV-2 antibodies globally,” said Ning Li, M.D., Ph.D., Junshi Biosciences’ chief executive officer. “At the same time, by leveraging Lilly’s global presence and capabilities, we have the potential to reach broader COVID-19 patient populations in a wider range of countries and regions.”

“As the number of global cases continues to grow, there is an urgent need to study multiple complementary approaches to address this disease,” said Daniel Skovronsky, M.D., Ph.D., Lilly’s chief scientific officer and president of Lilly Research Laboratories. “The data generated by Junshi Biosciences suggest the lead antibody may have appropriate properties to support testing its therapeutic use in patients as well as exploring its potential for preventing infection in at-risk individuals. We look forward to partnering with Junshi Biosciences to quickly begin testing this potential new therapy in clinical trials.”

Lilly will receive an exclusive license to conduct clinical development, manufacturing and distribution of products outside of Greater China. Junshi Biosciences will maintain all rights in Greater China.

About Junshi SARS-CoV-2 Antibodies
JS016 is a recombinant fully human monoclonal neutralizing antibody that is specific to the SARS-CoV-2 surface spike protein receptor binding domain and can effectively block the binding of viruses to host cell surface receptor ACE2. The project is jointly developed by Junshi Biosciences and Institute of Microbiology, Chinese Academy of Science.

At the beginning of the COVID-19 outbreak, Junshi Biosciences rapidly launched the research and development program of neutralizing antibodies to combat COVID-19. Within two months, the company has completed IND enabling pre-clinical studies, the process development and production for GLP toxicity study and GMP production of clinical material by leveraging the company’s platform technology. Junshi Biosciences and Lilly aim to submit an IND application and initiate clinical studies in the United States in the second quarter of the year. Meanwhile, the company is communicating actively with the Center for Drug Evaluation of the National Medical Products Administration to initiate the IND application submission in China as soon as possible.

About Junshi Biosciences
Established in 2012, Junshi Biosciences is committed to developing first-in-class and best-in-class drugs through original innovation and becoming a pioneer in the area of translational medicine to provide patients with effective and affordable treatment options. On December 24, 2018, Junshi Biosciences was listed on the Main Board of the Stock Exchange of Hong Kong with the stock code: 1877.HK. The Company has established a diversified R&D pipeline comprising 21 drug candidates with therapeutic areas covering cancer, metabolic diseases, autoimmune diseases, neurologic diseases, and infectious disease. Product types include monoclonal antibodies, fusion proteins, antibody-drug conjugates, and small molecule drugs. With a combined 33,000L fermentation capacity in two GMP-facilities at Shanghai and Suzhou, Junshi has established the manufacturing infrastructure to support commercialization and provide our partners and patients with high-quality products through a global supply chain network. For more information, please visit: http://junshipharma.com/en/Index.html

About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom. C-LLY


Zhi Li; zhi_li@junshipharma.com; (8621) 61058800 (Junshi Media)

Inger Chen; inger_chen@junshipharma.com; (8621) 61058800 (Junshi Investors)

Michael Levitan; mlevitan@soleburytrout.com; (646) 378-2920 (Junshi Investors; Solebury Trout)

Nicole Hebert; Nicole_Hebert@lilly.com; (317) 701-9984 (Lilly Media)

Kevin Hern; hern_kevin_r@lilly.com; (317) 277-1838 (Lilly Investors)

Indonesia reports 395 new coronavirus infections, 19 deaths

Indonesia reported on Monday 395 new coronavirus infections, taking the total in the Southeast Asian country to 11,587, said health ministry official Achmad Yurianto, Trend reports with reference to Reuters.

Yurianto reported 19 new coronavirus-related deaths, taking the total to 864, while 1,954 have recovered.

More than 86,000 people have been tested, he said.

Source: TREND News Agency

Govt spokesman confirms 211 other Indonesians recovered from COVID-19

Some 211 other people testing positive for the novel coronavirus disease 2019 (COVID-19) in Indonesia made a complete recovery as of Sunday, May 3, 2020, thereby taking the total to 1,876, a government spokesman noted.

“The number of deaths increased by 14 to reach 845,” government spokesman for the Handling of COVID-19 Achmad Yurianto stated during a press conference at the National Disaster Mitigation Agency (BNPB) Building in Jakarta on Sunday.

Yurianto noted that the number of patients under surveillance (PDPs) and people under surveillance (ODP) had reached 23,130 and 236,369 respectively.

Data indicated that the number of confirmed coronavirus cases in Indonesia had risen by 349 to reach 11,192, as of Sunday (May 3).

Yurianto noted that COVID-19 cases were reported in all 34 provinces in Indonesia.

The government had conducted testing of 112,965 swab samples taken from 83,012 people.

Yurianto stated that on the basis of the swab test, 11,192 people had tested positive for COVID-19, while 71,220 people tested negative for the virus.

Jakarta is still ranked first among the country’s 34 provinces in terms of the number of COVID-19 cases.

The number of confirmed coronavirus cases in Jakarta surged by 67 to reach 4,463, the number of people recovering from the disease rose by 120 to reach 632, while those dying from the virus increased by six to reach 398.

To thwart the spread of COVID-19, the Jakarta provincial government has enforced large-scale social restrictions, effective from April 10 to April 22, 2020.

The large-scale social restrictions were based on Jakarta Governor’s Decision No. 33 of 2020 aimed at containing the coronavirus outbreak in the capital, with a population of over nine million.

Source: Antara News

Indonesia’s airports apply operational efficiency amid COVID-19: AP II

Operational efficiency is critical to ensuring that Indonesia’s airline industry survives the impact of the new coronavirus pandemic, according to a top official of state-owned airport operator PT Angkasa Pura II (AP II).

“The airports, under AP II, are currently operating by adapting themselves to passenger and flight traffic,” Director of Engineering at PT Angkasa Pura II Agus Wialdi noted in a press statement received by ANTARA in Jakarta on Monday.

Despite operational efficiency being applied, AP II ensures that its airports continue to operate to maintain the country’s air transport connectivity, he stated.

In applying this operational efficiency strategy, the Soekarno-Hatta International Airport authority suspended the Skytrain service. In its place, a shuttle bus service has been started to connect passengers to all the airport’s terminals.

The Soekarno-Hatta International Airport’s Transit Oriented Development (TOD) has also been closed temporarily for implementing operational efficiency and facilitating the public to practice physical distancing measures, Wialdi noted.

By and large, the operational efficiency strategy is dominantly applied to lower electricity consumed by non-prioritized facilities at the airport, such as air conditioners, without overlooking the criticality of security, safety, health, and service. Electricity consumption can be reduced to 46 percent, he stated, adding that 19 airports, under AP II, had also applied operational efficiency in capital expenditures; in water consumption, up to 60 percent; and in the use of operational vehicles.

“With the application of this efficiency strategy, all airports, under AP II, can still operate optimally and also remain ready for serving flights permitted by Transportation Minister’s Regulation Number 25 of 2020,” he stated.

The ministerial regulation stipulates that all airlines are not allowed to serve domestic flight routes to cities that have enforced the large-scale social restriction and distancing measures in an endeavor to break the chain of COVID-19.

The coronavirus outbreak initially struck the Chinese city of Wuhan at the end of 2019, but it then spread to various parts of the world, including countries in the Asia-Pacific region.

The Indonesian government officially announced the country’s first confirmed cases on March 2.

Since then, central and regional governments across the country have continually striven to flatten the curve by imposing healthcare protocols and social restrictions. 

Source: Antara News

Data Protection Bill should incorporate sanction for data breach: MP

Sukamta, member of the House of Representatives’ (DPR’s) Commission I, put forth a suggestion that the Bill on Personal Data Protection (PDP) should encompass regulations on obligations of data managers and sanction for data breach.

“We will regulate the obligations of personal data managers, including sanctions in the event of a data breach like this. We will also outline the legal scope of data protection to include not only the surface web but also the deep web, including the dark web,” Sukamta noted in a statement here on Monday.

With reference to the breach, the DPR Commission I member pointed to the recent leakage of data of 15 million Tokopedia users. In fact, another report cited that the data of 91,000,000 Tokopedia users had been leaked.

“Leaked user data, such as those of the Tokopedia and Zoom meeting cases some time ago, were allegedly sold on this type of website (deep web). We hope that the regulations on data protection would later cover this,” he noted.

Sukamta emphasized that private data managers, such as public institutions and private companies, should be able to guarantee the security of their users’ data. Hence, their cybersecurity system should always be updated and improved by utilizing the best technology.

Meanwhile, he recommended to the public to change passwords regularly and protect personal accounts through a two-step verification process to minimize illegal access to their internet accounts.

“The data is akin to the importance attached to oil a few decades ago or like the worth of spices in the ancient archipelago that were believed to be more expensive than gold. In this digital world, data becomes very tempting to mine the dollar,” he pointed out.

In connection with the case of data leakage, he urged the government, in this case, the Ministry of Communication and Informatics, National Cyber and Crypto Agency (BSSN), the private sector, and the community, to jointly step up cyber vigil amid the COVID-19 pandemic.

“The government, in this case, the Ministry of Communication and Informatics and BSSN, private firms, such as companies that manage personal data and the public, as internet users, must unitedly strengthen cybersecurity. The Tokopedia (data leakage) case is an eye opener and a matter of concern for the cyber world in Indonesia,” Sukamta affirmed.

The PKS politician remarked that since April, he had urged the government to strengthen cybersecurity and resilience in the wake of the pandemic, as the use of online technology had risen significantly since several people were required to work from home (WFH) and students to study from home in accordance with the procedures of the Large-Scale Social Distancing (PSBB) measure imposed by the government to stem the transmission of the novel coronavirus.

Source: Antara News